[Pharmacological studies on sufoxazine (Y-8894). (II). Anti-anoxic effect].

Abstract

The anti-anoxic effect of sufoxazine was investigated in various cerebral anoxia models with mice, in comparison with those of various cerebroactive drugs. Sufoxazine reduced dose-dependently the duration of coma induced by a sublethal dose of KCN (1.8 mg/kg, i.v.), significantly stimulating recovery from the coma at 5 mg/kg, i.p. and 30 mg/kg, p.o. It also protected against a lethal dose of KCN (2.5 mg/kg, i.v.). Sufoxazine prolonged the survival time of mice subjected to hypobaric and normobaric hypoxia. Dihydroergotoxin and ifenprodil gave similar protection in the KCN-induced anoxia models, but produced adverse effects in the hypoxia models. Calcium hopantenate exerted similar but weak protection only at a dose as high as 300 mg/kg, i.p. These findings suggest that sufoxazine has an anti-anoxic action superior to those of the other cerebroactive drugs used.

• Authors: N Izumi, H Yasuda
• Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica (Nihon Yakurigaku Zasshi) Vol. 86 Issue 4 Pg. 323-8 (Oct 1985) ISSN: 0015-5691 [Print] Japan
• PMID: 4085932 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Morpholines
• Piperidines
• Dihydroergotoxine
• pantogab
• Pantothenic Acid
• gamma-Aminobutyric Acid
• sufoxazine
• Physostigmine
• Potassium Cyanide
• ifenprodil

Topics

• Animals
• Atmospheric Pressure
• Coma (chemically induced, drug therapy)
• Dihydroergotoxine (therapeutic use)
• Drug Therapy, Combination
• Hypoxia, Brain (chemically induced, drug therapy)
• Mice
• Morpholines (administration & dosage, therapeutic use)
• Pantothenic Acid (analogs & derivatives, therapeutic use)
• Physostigmine (administration & dosage)
• Piperidines (therapeutic use)
• Potassium Cyanide (antagonists & inhibitors)
• gamma-Aminobutyric Acid (analogs & derivatives, therapeutic use)